Suzanne Hendrix, Ph.D.

Suzanne Hendrix is the Founder and Chief Executive Officer of Pentara Corporation, a specialty Contract Research Organization (CRO) focusing on data management and statistics in Alzheimer’s disease (AD) and other degenerative diseases. Pentara has had integral involvement in over 80 AD clinical trials across all phases of development, with inputs into study design, data collection and analysis for small, medium and large pharmaceutical companies, non-profit groups and academic groups. She received her Ph.D. from Boston University working with Ralph D’Agostino and has over 30 years of clinical trials experience including regulatory submissions, across a broad range of indications for both drugs and devices.

Suzanne is an author of over 200 peer-reviewed publications and scientific presentations related to clinical trial results and statistical approaches for clinical trials, in AD and other degenerative diseases. She has extensive experience with composite scales for optimally measuring progression over time, which are also likely to be sensitive to disease modifying and symptomatic effects. She has extensively researched the relative timing of various cognitive, functional, behavioral and global changes in various stages of AD, within different clinical subpopulations, and for different mechanisms of action.